DG12BCZ
Brachytherapy Adrenal Glands to None with Californium 252 (Cf-252), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | G Endocrine System |
| Operation | 1 Brachytherapy |
| Body Part | 2 Adrenal Glands |
| Approach | B Low Dose Rate (LDR) |
| Device | C Californium 252 (Cf-252) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for the endocrine system involves placing a radioactive source directly into or immediately next to a gland, such as the thyroid or an adrenal gland, rather than aiming radiation at it from outside the body. Because the source sits so close to the target tissue, it can deliver a concentrated dose to the tumor while limiting exposure to surrounding structures.
This approach is used less often for endocrine tumors than external beam therapy, but it may be chosen when a tumor is well localized and accessible, or when a patient has already received prior external radiation and cannot tolerate additional beam exposure to the area. The radioactive material can be left in place temporarily or permanently, depending on the type of source and the treatment plan developed by the radiation oncology team.
Patients typically undergo a minor procedure to place the source, followed by a defined period during which the radiation is active, after which temporary sources are removed.
Anatomy & Axis Detail
Adrenal Glands
The adrenal glands sit atop each kidney and produce corticosteroids, mineralocorticoids, and catecholamines from distinct cortical and medullary regions, making them a site for both primary adrenal tumors and metastatic disease from lung, breast, or other primary cancers. Brachytherapy involving direct or image-guided placement of a radioactive source into an adrenal mass is a less common technique than external beam approaches, typically considered for a solitary lesion when a highly concentrated, localized dose is needed and surrounding structures such as the kidney, liver, or pancreas must be spared. Because the adrenal glands are retroperitoneal and mobile with respiration, source placement requires careful imaging guidance to ensure accurate targeting, and documentation should reflect whether one or both glands were treated.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Californium 252 (Cf-252)
Californium-252 is a neutron-emitting source rather than a gamma or beta emitter, used in specialized brachytherapy for radioresistant tumors such as certain cervical or head and neck cancers where neutrons' higher relative biological effectiveness offers an advantage. It is far less commonly used than the gamma-emitting seed isotopes and is documented separately because its neutron output changes tissue interaction and shielding requirements.
Coding & Documentation
The operative note must document direct placement of a radioactive source in or adjacent to the endocrine gland, along with the specific gland treated, to support a code from this family. Coders should confirm whether the source was temporary or permanent, since this can affect qualifier selection and whether a separate removal procedure needs to be captured later. A common mistake is confusing brachytherapy with radioactive iodine ablation for thyroid disease, which is often administered orally or systemically rather than through direct implantation and may not be coded as a procedure in this section at all. Another pitfall is failing to code the placement device or applicator separately when the documentation calls for it under coding guidelines.